Therapeutic Solutions International Inc (TSOI)

$0.00 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 725,000
Avg Vol 2,270,846
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 50%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and health...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 295 7208
Address:
701 Wild Rose Lane, Elk City, United States
jmarcello
jmarcello May. 13 at 2:50 PM
$TSOI We have asserted before and reiterate here, the cells are likely already rightfully belonging to TSOI (other than your processing services) if in fact they are the "claimed" cell of the 176' patent. Without proper cGMP paperwork and logbook entries, the alleged "free aliquots" coming from Master Cell Bank One and being received at UM by Dr. Ricordi are in question as to their authenticity. How do we even know the cells you are to provide us are in fact the clinical grade cells which exist only in Master Cell Bank One? The short answer is we don't and without proper documentation those "doses" might be considered adulterated and/or misbranded drugs.
0 · Reply
jmarcello
jmarcello May. 13 at 2:49 PM
$TSOI Note, this statement appears to predate our acquisition of JadiCell patent rights as described under our license with Jadi Cell LLC, but the aliquots mentioned are the subject of our agreement with you. However, you are charging us (which TSOI agreed to pay as a means of expediting the IND transfer and allowing UM to reap some benefit for supporting the research) for clinical grade cells that you yourself got for free but have not actually produced any contracts, agreements, certificates of analysis, temperature logs, etc. in receipt of them.
0 · Reply
jmarcello
jmarcello May. 13 at 2:49 PM
$TSOI Depositions of Dis. Ricordi and Patel Relevant to Underlying Patent. In that deposition some interesting responses were made by Dr. Ricordi, including: Q. Di. Ricordi Have you performed any other service for Jadi Cell? A. No, no other service, except that - except in the cell aliquots from the Master Cell Bank that we used for the trial. Q. Okay. So you're referring to the use of Jadi cells in a clinical trial? A. Yeah, there were kind enough to provide it at no charge this aliquots when it was the COVID pandemic emergency.
0 · Reply
jmarcello
jmarcello May. 13 at 2:48 PM
$TSOI On August 26, 2022, Dr. Ricordi gave sworn testimony under oath in the UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD; RESTEM, LLC., VS. JADI CELL, LLC in Case # IPR2021-01535.
0 · Reply
jmarcello
jmarcello May. 13 at 2:48 PM
$TSOI You should be aware, but in the odd chance you are not, on September 29, 2021, just 14 days after we completed our final licensing agreement with JadiCell, LLC, an Inter Partes Review (IPR) was filed at the US Patent and Trademark Office before the Patent Trial and Appeal Board by Restem LLC ("Restem"). Both Dr. Patel (see Exhibit #99.1) and Ricordi (see Exhibit #99.12) have given sworn testimony.
0 · Reply
jmarcello
jmarcello May. 13 at 2:47 PM
$TSOI In fact, after going through the document dump provided by UM in detail, there appear to be no agreements covering anything related to obtaining "free aliquots" from Amit Patel cum Jadi Cell LLC, the Phase 1/2, the six eND's you applied for prior to our acquisition in Feb 2021; nor for the two you did after our ownership without our permission or consent; nor the two papers published, the assay work itself, the filing of phase 3 IND, or the letter of authorization on August 12, 2021, sent to the FDA to authorize Arugula Sciences LLC to reference and rely on IND 19757 in support of Arugula Sciences LLC IND applications for Muscular Dystrophies, Eosinophilic Disorders, and Sarcoidosis.
0 · Reply
jmarcello
jmarcello May. 13 at 2:47 PM
$TSOI Interesting to note, under the CTE/TBI licensing arrangement, Dr. Patel and Jadi Cell LLC had 115 million shares of ISOI. News like being involved in a Phase 1/2 and then Phase 3 study could realistically help improve the price per share of stock held in TSOI (in fact, it did ...). As of today, neither Jadi Cell LLC nor UM has produced any agreement between the parties other than the MTA of 2018 which Mr. Black, legal counsel for Jadi Cell LLC said did not cover any clinical trials.
0 · Reply
dannymac65
dannymac65 May. 13 at 2:45 PM
$TSOI Where is PumpersPumper and some Warren Buffett quotes?
0 · Reply
jmarcello
jmarcello May. 13 at 2:45 PM
$TSOI During negotiations, Patel stated to Timothy Dixon ("Dixon"), CEO of SOI, that part of what was being licensed included the Phase 2 Investigational New Drug Application (the "IND" and/or "IND# 19757") that had been applied for as a Phase 3 study by University Miami ("UM").
0 · Reply
jmarcello
jmarcello May. 13 at 2:45 PM
$TSOI On February 9, 2021, Jadi Cell LLC accepted a $15,000,000 convertible promissory note ("CPN") (see attached Exhibit # 99.13) for exclusive world-wide patent rights to US Patent 9,803,176 B2 (the "Patent"), and the drug master file (the Drug Master File), and master cell bank one (the "Master Cell Bank One') for all lung indications, including complications from COVID-19.
0 · Reply
Latest News on TSOI
No data available.
jmarcello
jmarcello May. 13 at 2:50 PM
$TSOI We have asserted before and reiterate here, the cells are likely already rightfully belonging to TSOI (other than your processing services) if in fact they are the "claimed" cell of the 176' patent. Without proper cGMP paperwork and logbook entries, the alleged "free aliquots" coming from Master Cell Bank One and being received at UM by Dr. Ricordi are in question as to their authenticity. How do we even know the cells you are to provide us are in fact the clinical grade cells which exist only in Master Cell Bank One? The short answer is we don't and without proper documentation those "doses" might be considered adulterated and/or misbranded drugs.
0 · Reply
jmarcello
jmarcello May. 13 at 2:49 PM
$TSOI Note, this statement appears to predate our acquisition of JadiCell patent rights as described under our license with Jadi Cell LLC, but the aliquots mentioned are the subject of our agreement with you. However, you are charging us (which TSOI agreed to pay as a means of expediting the IND transfer and allowing UM to reap some benefit for supporting the research) for clinical grade cells that you yourself got for free but have not actually produced any contracts, agreements, certificates of analysis, temperature logs, etc. in receipt of them.
0 · Reply
jmarcello
jmarcello May. 13 at 2:49 PM
$TSOI Depositions of Dis. Ricordi and Patel Relevant to Underlying Patent. In that deposition some interesting responses were made by Dr. Ricordi, including: Q. Di. Ricordi Have you performed any other service for Jadi Cell? A. No, no other service, except that - except in the cell aliquots from the Master Cell Bank that we used for the trial. Q. Okay. So you're referring to the use of Jadi cells in a clinical trial? A. Yeah, there were kind enough to provide it at no charge this aliquots when it was the COVID pandemic emergency.
0 · Reply
jmarcello
jmarcello May. 13 at 2:48 PM
$TSOI On August 26, 2022, Dr. Ricordi gave sworn testimony under oath in the UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD; RESTEM, LLC., VS. JADI CELL, LLC in Case # IPR2021-01535.
0 · Reply
jmarcello
jmarcello May. 13 at 2:48 PM
$TSOI You should be aware, but in the odd chance you are not, on September 29, 2021, just 14 days after we completed our final licensing agreement with JadiCell, LLC, an Inter Partes Review (IPR) was filed at the US Patent and Trademark Office before the Patent Trial and Appeal Board by Restem LLC ("Restem"). Both Dr. Patel (see Exhibit #99.1) and Ricordi (see Exhibit #99.12) have given sworn testimony.
0 · Reply
jmarcello
jmarcello May. 13 at 2:47 PM
$TSOI In fact, after going through the document dump provided by UM in detail, there appear to be no agreements covering anything related to obtaining "free aliquots" from Amit Patel cum Jadi Cell LLC, the Phase 1/2, the six eND's you applied for prior to our acquisition in Feb 2021; nor for the two you did after our ownership without our permission or consent; nor the two papers published, the assay work itself, the filing of phase 3 IND, or the letter of authorization on August 12, 2021, sent to the FDA to authorize Arugula Sciences LLC to reference and rely on IND 19757 in support of Arugula Sciences LLC IND applications for Muscular Dystrophies, Eosinophilic Disorders, and Sarcoidosis.
0 · Reply
jmarcello
jmarcello May. 13 at 2:47 PM
$TSOI Interesting to note, under the CTE/TBI licensing arrangement, Dr. Patel and Jadi Cell LLC had 115 million shares of ISOI. News like being involved in a Phase 1/2 and then Phase 3 study could realistically help improve the price per share of stock held in TSOI (in fact, it did ...). As of today, neither Jadi Cell LLC nor UM has produced any agreement between the parties other than the MTA of 2018 which Mr. Black, legal counsel for Jadi Cell LLC said did not cover any clinical trials.
0 · Reply
dannymac65
dannymac65 May. 13 at 2:45 PM
$TSOI Where is PumpersPumper and some Warren Buffett quotes?
0 · Reply
jmarcello
jmarcello May. 13 at 2:45 PM
$TSOI During negotiations, Patel stated to Timothy Dixon ("Dixon"), CEO of SOI, that part of what was being licensed included the Phase 2 Investigational New Drug Application (the "IND" and/or "IND# 19757") that had been applied for as a Phase 3 study by University Miami ("UM").
0 · Reply
jmarcello
jmarcello May. 13 at 2:45 PM
$TSOI On February 9, 2021, Jadi Cell LLC accepted a $15,000,000 convertible promissory note ("CPN") (see attached Exhibit # 99.13) for exclusive world-wide patent rights to US Patent 9,803,176 B2 (the "Patent"), and the drug master file (the Drug Master File), and master cell bank one (the "Master Cell Bank One') for all lung indications, including complications from COVID-19.
0 · Reply
jmarcello
jmarcello May. 13 at 2:44 PM
$TSOI RELEVANT FACTS Underlying Agreement with Jadi Cell LLC and Licensed Patent. On or about Nov/Dec 2020, Jadi Cell LLC ("JADI"), through their sole member, Dr. Amit Patel ("Patel"), approached TSOI through their director, Dr. Thomas Ichim ("Ichim"), about licensing JADI's JadiCell mesenchymal stem cell ("Jadi Cell") in the area of COVID-19 lung damage (US Patent 9,803,176 B2 (the "Patent"), and the drug master file (the Drug Master File), and master cell bank one (the "Master Cell Bank One") for all lung indications, including complications from COVID-19. This is a similar licensing arrangement that is for use of the same stem cell exclusively for CTE/TBI.
0 · Reply
jmarcello
jmarcello May. 13 at 2:43 PM
$TSOI We request the associated description of the cell numbers received and characterization documentation, along with temperature logs, chain of custody logs, and regulatory paperwork including the GMP paperwork received from Jadi Cell LLC for the "free aliquots" that were delivered. In addition, if the cells were delivered by a third-party courier service certified for GMP biologics transport, we would also request those documents as well. As mentioned in our Zoom call, please find below the relevant facts for your review.
0 · Reply
jmarcello
jmarcello May. 13 at 2:43 PM
$TSOI lets start from the upper Dear Dr. Kenyon and Mr. Peral: Thank you for the Zoom call this morning. You will recall we did attempt to have a call a few weeks ago, but no one was available at the University until January 11th. As we stated, after internal audit and discovery of disturbing information, we concluded we must seek validation that the cell doses that are to be used as referenced in the cleared phase 3 IND, and are the subject of our agreement, are the claimed cells of the '176 patent (US Patent 9,803,176 B2).
0 · Reply
jmarcello
jmarcello May. 13 at 2:43 PM
$TSOI
0 · Reply
jmarcello
jmarcello May. 13 at 2:42 PM
$TSOI At the end of the day the uber reality is that based on actions taken by Dis. Ricordi and Patel with the sanction of UM and Jadi Cell LLC, grave concerns regarding the proper documentation, process and control of living drugs based upon testimonies of the good doctors and the lack of documentation or written disclosures by UM and Jadi Cell LLC, SOI hereby demands that all documentation regarding withdrawals of aliquots from Master Cell Bank One, there transportation, storage, processing for assay and use in administering them to any and all patients be immediately turned over so that we - as well as the FDA - be assured the drugs, and hence, the data, has not been tainted.
0 · Reply
jmarcello
jmarcello May. 13 at 2:42 PM
$TSOI We have just discovered in the last week (December 2022) that on August 12, 2021, just one week after FDA cleared the phase 3 IND, Di. Ricordi sent an LOA to FDA for the purpose of authorizing Arugula Sciences LLC to reference and rely on IND 19757 in support of Arugula Sciences LLC IND applications for Muscular Dystrophies, Eosinophilic Disorders, and Sarcoidosis. Six days later we would have a telephonic conversation on zoom with Ricordi, Patel, Dr. Ichim, Mr. Dixon, and several others from UM tech transfer dept. and none of you thought this should be disclosed to us?
0 · Reply
jmarcello
jmarcello May. 13 at 2:41 PM
$TSOI
0 · Reply
dannymac65
dannymac65 May. 13 at 2:41 PM
$TSOI Dixy, the internet tough guy and wife beater hiding out in Idaho from his VicTims and bill collectors. Good news for fake Dr. Timmy boi? Lying-thieving psychopaths actually sleep well at night.
0 · Reply
jmarcello
jmarcello May. 13 at 2:40 PM
$TSOI And then again on October 1, 2021, Di. Ricordi again authorizes another physician to use our cells without our permission of awareness. At this point there is no chance for the argument that Dr. Ricordi was unaware of TSOI. During this time, we were in the middle of negotiations for the IND transfer. Where is the disclosure of these actions? You put SOI at risk when you conducted these emergency uses yet failed to notify or disclose. Why?
0 · Reply
jmarcello
jmarcello May. 13 at 2:39 PM
$TSOI
0 · Reply
dannymac65
dannymac65 May. 13 at 2:34 PM
$TSOI Tim Dixon doesn't like to pay his bills. Good thing "Dr." Tom Ichim publicly declared he would financially support TSLie. That's good news for Kyle Shepard and the debt collectors.
0 · Reply
jmarcello
jmarcello May. 13 at 2:32 PM
$TSOI Speaking of using cells to treat patients, whatever happened to the patients that were treated with JadiCells from Master Cell Bank One between 2/9/2021 until now? Where is TSOIs written permission to use those cells for treatment? Where is the disclosure documentation and custodial documentation for those cells?
1 · Reply